NS-HGlio

by Neosoma  · Based in United States → — Advancing Brain Cancer Care with AI-Powered MRI Analysis
Neurosurgery Oncology Radiology
Website
Claim this tool
Is this the maker? Claim the company →

Priced based on mri volume
Regulatory Status Disclosed

Overview

Neosoma is an innovative medical technology company focused on advancing the treatment of brain cancers through an integrated portfolio of artificial intelligence-based software products combined with a Clinical Management Software Platform. Its comprehensive SaaS solution is designed to serve the multidisciplinary neuro-oncology clinical team, researchers, and clinical trials. The company’s technology facilitates practitioners to analyze magnetic resonance imaging (MRI) sequences and provides an automated response assessment about tumors, such as glioblastoma, enabling doctors and clinicians to instantaneously access the status of the disease through digital images.

The Neosoma Platform includes a portfolio of highly-optimized, indication-specific software medical devices that map and measure compartments of tumors and track lesions longitudinally, delivering key insights in near-real-time to support clinical decisions and research. Its technology is PACS-integrated, interoperable with radiation treatment and surgical planning systems, and web-based for easy and secure access. The platform is cloud-based, allowing for the processing of a virtually unlimited number of patient MRIs and tracking of identified brain lesions.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Semi-automatic segmentation of high-grade glioma (enhancing tissue, T2/FLAIR hyperintensity, necrosis + cavity)
  • Volumetric quantification of tumor compartments
  • 3D visualization and interactive contour editing tools
  • Longitudinal tracking and analysis of tumor changes over time
  • PACS integration for automated DICOM study sending and deep linking
  • Interoperability with radiation treatment and surgical planning systems (e.g., Eclipse, MIM, Gamma Plan, Stealth)
  • Web-based interface for easy and secure access
  • MRI protocol tolerant (no changes to acquisition protocols needed)
  • Supports tumor burden and Residual Tumor Volume (RTV) assessment
  • Reimbursable via Category 3 CPT Codes (0865T, 0866T)

Use Cases

  • Treatment response monitoring in clinical practice and trials
  • Radiation treatment planning (automated GTV contouring)
  • Surgical planning and intra-operative targeting
  • Longitudinal assessment of high-grade gliomas
  • Patient counseling and visualization of tumor changes
  • Clinical research and re-analysis of historical clinical trials data

What Physicians Need to Know

Brain MRI/CT Analysis
NS-HGlio is designed for the semi-automatic labeling, visualization, and volumetric quantification of high-grade brain glioma (WHO grade 3 astrocytoma, WHO grade 4 astrocytoma, and WHO grade 4 glioblastoma) from standard MRI images. It automatically quantifies enhancing tissue, T2/FLAIR hyperintensity, and necrosis + cavity from standard MRI sequences at the voxel level. The software supports tumor burden and residual tumor volume (RTV) assessment, automated Gross Tumor Volume (GTV) contouring for radiation therapy and surgical planning, and patient counseling. It also performs longitudinal analysis through automated co-registration of sequences and empirical comparison of current time points with prior ones at both total tumor burden and compartment levels. NS-HGlio has been shown to reduce segmentation time significantly (pre-operative: 15 seconds vs. 210.5 seconds; post-operative: 15 seconds vs. 179 seconds).
Neurodegenerative Disease Screening
NS-HGlio is specifically developed for the analysis of high-grade gliomas and is not indicated for general neurodegenerative disease screening.
Physician Tip

NS-HGlio is intended for use by qualified clinical personnel as an additional source of information and not as the sole diagnostic metric. Medical professionals must finalize (confirm or modify) the contours generated by the software using an external platform that supports DICOM viewing/editing functions. The software is intended for adult patients (18 years or older) with pathologically proven high-grade glioma. It is not to be used for primary diagnosis. NS-HGlio can be used for visualization, documentation, treatment response monitoring, radiation planning, intra-operative targeting, and estimation of Residual Tumor Volume. The software aims to eliminate inter-rater and intra-rater variability in volumetric measurements, providing accurate and repeatable quantification of tumor volumes.

NS-HGlio is designed to integrate with existing PACS, EMR, and research systems through an 'Edge System' technology. It can also be accessed via a standalone client dashboard for visualization, editing, and structured reporting, which supports virtual multidisciplinary team meetings with videoconferencing capabilities. The platform is cloud-based and integrates with PACS for automated sending of DICOM studies for analysis, including one-click deep linking from PACS to the Neosoma system. It allows for the import of GTV auto-contours into treatment planning systems such as Eclipse, MIM, Gamma Plan, and Stealth. NS-HGlio is FDA-cleared.

Details

Category Neurology AI, Oncology AI, Radiology & Imaging AI
Pricing Priced based on mri volume
DeploymentCloud-based, web-based interface
Compliance
BAA Available Yes AI-estimated
HIPAA Compliant Yes AI-estimated
FDA Status Yes AI-estimated
Integrations
EHR Not specified
Specialties Neurosurgery, Oncology, Radiology

What the Web Says

NS-HGlio is an FDA-cleared AI-based software platform developed by Neosoma for the segmentation and volumetric measurement of high-grade gliomas (HGG) from MRI scans. It aims to provide accurate, repeatable, and generalizable measurements of enhancing and T2/FLAIR hyperintensity/edema volumes, which are crucial for monitoring treatment response and informing clinical decisions. The technology has been published in peer-reviewed journals, highlighting its development, validation, and performance.

Overall: Positive

Strengths

  • Accurate and repeatable in quantifying HGG enhancing and edema volumes.
  • Generalizable across different datasets, institutions, and MRI vendors.
  • Significantly reduces segmentation time compared to manual methods.
  • Eliminates inter-rater and intra-rater variability in measurements.
  • Can be used for visualization, documentation, treatment response monitoring, radiation planning, and estimation of residual tumor volume.
  • FDA-cleared, allowing for routine implementation in clinical care.

Limitations

  • Limitations in distinguishing pseudo-progression from tumor progression.
  • T2-FLAIR-derived volumes can vary significantly between AI platforms, with potential over-segmentation beyond the tumor region.
  • May have erroneous segmentation of edema in cerebellar hemispheres due to pulsation artifacts in a small percentage of cases.
  • May miss small enhancing lesions below 5 mm in diameter in some cases.
  • No web reviews from physicians, healthcare IT, tech reviewers, Reddit, G2, or Capterra were found directly for NS-HGlio.

Based on reviews from: innolitics.com, nih.gov, g2.com, neosomainc.com, oup.com, healthaidb.com, physicianaitools.com, trustradius.com, softwaresuggest.com, capterra.com, reddit.com, analyzedirect.com, researcher.life, africaresearchconnects.com

Last updated: 2026-10-31

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate NS-HGlio

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Neuro-Oncology Advances (Oxford Academic)
NS-HGlio: A generalizable and repeatable HGG segmentation and volumetric measurement AI algorithm for the longitudinal MRI assessment to inform RANO in trials and clinics
This peer-reviewed article details the development and validation of NS-HGlio, an AI algorithm for segmenting and volumetrically measuring high-grade gliomas (HGG) on MRI scans to inform Response Assessment in Neuro-oncology (RANO) criteria in clinical trials and practice.
2023-01
AnalyzeDirect Publications Database
NS-HGlio: A Generalizable and Repeatable HGG Segmentation and Volumetric measurement AI Algorithm for the Longitudinal MRI Assessment to Inform RANO in Trials and Clinics
This publication highlights the use of Analyze 14.0 in creating the ground truth data for the NS-HGlio AI algorithm, which focuses on generalizable and repeatable HGG segmentation and volumetric measurement for longitudinal MRI assessment.
2022-12
neosomainc.com
Neosoma Announces FDA 510(k) Clearance for Neosoma HGG
Neosoma announced receiving U.S. Food and Drug Administration (FDA) 510(k) clearance for Neosoma HGG (NS-HGlio), its AI-based neuro-oncology software for three-dimensional longitudinal tumor analysis and quantification of high-grade gliomas.
2022-09
neosomainc.com
Neuro-Oncology Advances Publishes About Neosoma's Technology
Neosoma announced that the technology and development of Neosoma HGG (NS-HGlio) was published in Neuro-Oncology Advances, a high-impact peer-reviewed journal.
2023-01
fda.gov
NS-HGlio 510(k) Premarket Notification
This FDA 510(k) premarket notification document provides details on NS-HGlio, including its classification as an automated radiological image processing software, its intended use for semi-automatic labeling, visualization, and volumetric quantification of high-grade brain glioma, and its regulatory class.
2022-09
healthcareaiops.com
FDA 510(k) K221738: NS-HGlio by Neosoma, Inc.
This entry confirms the FDA 510(k) clearance for NS-HGlio by Neosoma, Inc., on September 27, 2022, under the AI-associated product code QIH.
2022-09
neosomainc.com
Neosoma's NS-HGlio AI Technology Utilized in New Study on Recurrent Glioblastoma
A new study published in CNS Oncology utilized Neosoma's NS-HGlio AI technology to perform precise measurements of tumor volumes in patients with recurrent glioblastoma, demonstrating how AI and advanced imaging can help predict survival.
unknown
Neuro-Oncology Advances (Oxford Academic)
Neosoma HGG significantly reduced segmentation time
A study published in Neuro-Oncology Advances found that Neosoma HGG significantly reduced the time required for tumor segmentation compared to manual methods, while maintaining consistent contrast-enhancing tumor volumes across AI platforms.
2026-02

Videos

Product demos, reviews, and walkthroughs for NS-HGlio.

View all on YouTube

Frequently Asked Questions

NS-HGlio is an AI-driven software that segments and quantifies high-grade gliomas (HGG) from MRI scans, providing objective volumetric measurements of enhancing tissue, T2/FLAIR hyperintensity, and necrosis + cavity. This aids in monitoring treatment response, radiation planning, surgical planning, and patient counseling, by offering accurate and repeatable tumor volume assessments.
NS-HGlio is an FDA-cleared Software as a Medical Device (SaMD) for the semi-automatic labeling, visualization, and volumetric quantification of high-grade brain glioma. It is intended for use by qualified clinical personnel as an additional source of information and not for primary diagnosis.
While NS-HGlio offers automated segmentation, manual segmentation by neuroradiologists is a traditional alternative, though it is more time-consuming and can have inter-rater and intra-rater variability. Other AI-based platforms also exist for tumor volume quantification, and NS-HGlio has been compared to some of these in studies.
NS-HGlio is not intended for primary diagnosis and should be used as an adjunct tool by qualified clinical personnel. A key limitation identified in studies is its performance in distinguishing pseudo-progression from true tumor progression. Additionally, AI in neuroimaging generally has limits regarding sensitive data dependence, explainability, and potential uneven performance across diverse patient groups.
NS-HGlio significantly reduces the time required for volumetric segmentation compared to manual methods, improving efficiency. It also aims to eliminate inter-rater and intra-rater variability in tumor measurements, providing more objective and standardized assessments for treatment response monitoring and clinical trials.
Yes, NS-HGlio is designed to be interoperable and can import auto-contours into various treatment planning systems such as Eclipse, MIM, Gamma Plan, and Stealth. It also operates with Neosoma's proprietary Clinical Management Software Platform to centralize clinical data and streamline patient care.

Related Tools

Parkiwatch
Koios Care
Neurology AI
Parkiwatch by Koios Care is a Class IIa Software as a Medical Device (EU MDR 2017/745) for continuous, passive detection and quantitative assessment of kinematic patterns representative of tremor, bradykinesia, and dyskinesia in adults with Parkinson's Disease.
Paid
CortiCare (Virtual EEG Department)
CortiCare
Neurology AI
CortiCare offers 24/7 remote EEG monitoring and interpretation services, functioning as a virtual EEG department to assist hospitals and neurology practices in identifying seizures and other neurological conditions.
NeuroAstra
Avinya NeuroTech
Clinical Decision Support & Reference
NeuroAstra is an AI-enabled EEG analysis and reporting software that provides a multimodal clinical EEG web platform with Co-Pilot AI to help neuro care teams detect abnormal trends faster and standardize reporting.
Cercare Medical Oncology Virtual Expert
Cercare Medical
Neurology AI
Cercare Medical's Oncology Virtual Expert is an AI-powered brain tumor segmentation module that provides fast, consistent, and semi-automated tumor analysis from standard MRI data, designed for on-premise deployment within existing clinical radiology workflows.
CoLumbo C-Spine
Smart Soft Healthcare AD
Clinical Decision Support & Reference
CoLumbo C-Spine is an AI-powered software that processes and analyzes cervical spine MRI exams, assisting clinicians in diagnosis and assessment.
MeRT System
Wave Neuroscience
Mental & Behavioral Health AI
MeRT (Magnetic e-Resonance Therapy) is an advanced, personalized form of TMS that uses your own brainwave data to guide treatment. It's a non-invasive, drug-free option designed to help the brain communicate more efficiently so symptoms of conditions like depression, anxiety, PTSD, TBI, autism, and more can improve.
Paid

See all Neurology AI tools →

More from Neosoma

Neosoma Brain Mets
Neosoma
Neurology AI
Neosoma Brain Mets is an FDA-cleared AI-powered software for rapid MRI assessment and auto-contouring of brain metastases, providing near-real-time insights for multidisciplinary neuro-oncology teams.
Neosoma Platform
Neosoma
Clinical Decision Support & Reference
The Neosoma Platform is a cloud-based, FDA-cleared AI tool for neuro-oncology, providing automated tumor mapping, lesion tracking, and real-time insights for brain metastases and gliomas.
Volume-based

View company profile →

Suggest an Edit → | Report an issue | Last Verified: 2026-04-18 | First Added: 2026-04-18

Investors who backed NS-HGlio

Funded through the company that built this tool.

Verge Healthtech Fund
VC T3
Singapore, Singapore
$250k-$1M
Verge Healthtech Fund is a Singapore-based early-stage healthtech specialist at verge.fund with a Singapore LinkedIn presence and active Crunchbase profile, focused on…
AI/ML in Healthcare Diagnostics
R3i Ventures
VC T3
Singapore, Singapore
$250k-$1M
R3i Ventures is the venture investment arm of R3i Capital, a healthcare-focused investment platform whose name and r3icapital.ai domain suggest a thesis…
AI/ML in Healthcare Diagnostics
AI Tool Finder
AI-powered search. Results may not be comprehensive.